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Personalized medicine holds great promise for cancer treatment, with the potential to address challenges
associated with drug sensitivity and interpatient variability. Circulating tumor cells (CTC) can be useful
for screening cancer drugs as they may reﬂect the severity and heterogeneity of primary tumors. Here
we present a platform for rapidly evaluating individualized drug susceptibility. Treatment efﬁcacy is
evaluated directly in blood, employing a relevant environment for drug administration, and assessed
by comparison of CTC counts in treated and control samples. Multiple drugs at varying concentrations
are evaluated simultaneously to predict an appropriate therapy for individual patients.
 2013 The Authors. Published by Elsevier Ireland Ltd. This is anopenaccess article under theCCBY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
It is increasingly apparent that the most effective treatment for
a cancer patient is a personalized approach based on predictive
criteria for that individual. Traditional practice to achieve this goal
has been to identify predictors of sensitivity or resistance in malig-
nant cells. For example, it has been shown that panitumumab can
be an effective therapy for colorectal cancer patients, but only in
patients without KRAS mutation, which renders the treatment
ineffective [1]. Thus, patients are screened for mutated KRAS prior
to panitumumab treatment. Patients with non-small-cell lung can-
cer are evaluated for speciﬁcally mutated EGFR prior to being
placed on geﬁtinib [2]. However, for more general chemotherapeu-
tics, such as taxanes, no single mutation or marker has been iden-
tiﬁed that will serve as a reliable predictor of patient response.
Chemotherapeutic resistance, both intrinsic and acquired, is a sig-
niﬁcant problem and is believed to result in failure in more than
90% of patients with metastatic disease [3]. In an attempt to deter-
mine patient-speciﬁc sensitivity to cytotoxic and cytostatic agents,
studies have been conducted wherein tumor cells are biopsied and
treated ex vivo. Unfortunately no signiﬁcant beneﬁt has been foundin these types of assays because sensitivity ex vivo does not neces-
sarily translate to a similar response in vivo [4]. This is likely due in
part to spatial heterogeneity within tumors and the fact that biop-
sies only sample a small section of a tumor [5,6], and in part a con-
sequence of the environment in which the cells are treated [7].
In recent years much interest has been focused on circulating
tumor cells (CTC) [8]. Many studies have found that CTC appear
early in the disease, and their prevalence in blood correlates with
disease severity [9–12]. Clinicians are beginning to view CTC iso-
lated from blood draws as a ‘ﬂuid biopsy’, something of a snapshot
of the current state of a dynamic tumor, and CTC are believed to re-
ﬂect in some way the breadth of tumor heterogeneity [13]. Indeed,
the case has been made that CTC are the relevant cancer cell
subpopulation to target for therapy based on the fact that 90% of
cancer deaths are due to metastasis [14]. In addition, the circula-
tory system, within which cancer cells are termed CTC, is the primary
route of metastasis [15]. As such, CTC are being investigated on a
patient-to-patient level for characterization purposes, such as
epithelial-to-mesenchymal (EMT) state [16] and detection of
surface markers that correlate with speciﬁc drug response [17].
We recently reported a technique for the isolation of CTC from
patient blood in a relatively simple device using off-the-shelf
components [18,19]. The device is modeled on an inﬂamed post-
capillary venule and is functionalized with recombinant human
E-selectin to rapidly bind ﬂowing cells and anti-EpCAM antibodies
to ﬁrmly adhere cancer cells. It has been suggested that E-selectin
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metastatic cells [20–22]. In this paper we present a technique to
rapidly screen patient samples for sensitivity to multiple chemo-
therapeutics in a relevant setting. To accomplish this, blood
samples from a patient diagnosed with metastatic cancer are split
into multiple aliquots with chemotherapeutics introduced at clin-
ically relevant dosages to treat the CTC in situ. Subsequently, the
CTC are isolated from the paired aliquots and enumerated. Reduc-
tions in CTC count are interpreted as drug sensitivities. This
assumption was validated using drug-sensitive cell lines spiked
into normal whole blood. It is concluded that one may successfully
detect signiﬁcant CTC count reductions using this approach,
providing a platform upon which to make informed therapeutic
decisions. This technique has the potential for additional use as a
companion tool to detect acquired resistance throughout treatment.
2. Materials and methods
2.1. Cell culture
BT20 and PC3 cells were purchased from the American Type Culture Collection
(ATCC, Manassas, VA). BT20 cells were grown in Eagle’s Modiﬁed Medium (ATCC)
supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin–streptomycin (Lonza, Basel, Switzerland). PC3 cells were
grown in RPMI 1640 media (VWR, Randor, PA) supplemented with 10% FBS and
1% penicillin–streptomycin. Cells were maintained at 37 C and 5% CO2.
2.2. Antibodies and reagents
Anti-EpCAM (clone 158210), anti-EpCAM-FITC (clone 158206) antibodies,
mouse IgG2b-FITC isotype control, and recombinant human-E-selectin were pur-
chased from R&D Systems (Minneapolis, MN). Anti-CD45-APC (clone HI30) anti-
body, anti-sialyl Lewisx antibody (clone CSLEX1), mouse IgG1 isotype control, and
Annexin V-APC kit were obtained from BD Biosciences (San Jose, CA). Anti-Ep-
CAM-FITC (clone HEA-125) was obtained from Miltenyi Biotec (Auburn, CA). Anti-
mouse IgG1-Alexa488 secondary antibody was purchased from Life Technologies
(Grand Island, NY). Halloysite nanotubes were a gift from NaturalNano (Rochester,
NY). Ficoll-Paque was purchased from GE Healthcare (Waukesha, WI). Erythrocyte
lysis buffer was obtained from Qaigen (Germantown, MD). Docetaxel, mitoxan-
trone, and calcium carbonate were purchased from Sigma Aldrich (St. Louis, MO).
Doxorubicin was purchased from Sellek-Pﬁzer (Houston, TX). ViaCount Viability
Kit was purchased from Millipore (Billerica, MA). Hank’s balanced salt solution
(HBSS), phosphate-buffered saline (PBS), PBS supplemented with calcium and mag-
nesium, and trypsin were purchased from Life Technologies (Grand Island, NY).
Paraformaldehyde was acquired from Electron Microscopy Sciences (Hatﬁeld, PA).
DAPI was obtained from Vector Laboratories (Burlingame, CA). Bovine serum albu-
min (BSA) was purchased from Sigma Aldrich (St. Louis, MO). Dimethyl sulfoxide
(DMSO) was obtained from Avantor Performance Materials Inc. (Center Valley, PA).
2.3. Preparation of selectin-functionalized microtubes
Selectin-functionalized microtubes for cancer cell isolation were prepared as
previously described [18,19]. Microrenathane tubing was washed with ethanol
and distilled water, then coated with 0.02 wt% poly-L-lysine (1:250) and 6.6 wt%
halloysite nanotubes. The tubes were subsequently washed with distilled water
and allowed to cure overnight at RT. The halloysite-coated microtubes were then
perfused with 20 lg/mL Protein-G and allowed to incubate for 2 h at RT. A solution
of 10 lg/mL E-selectin-Fc chimera and 50 lg/mL anti-EpCAM antibody was then
pulled into the microtubes. The tubes were treated with this solution for 2 h at
RT, and then blocked with 5% milk for 1 h at RT.
2.4. Determination of false positive rate and capture efﬁciency
For the determination of false positive rates, 10 mL of whole blood was drawn
from four healthy volunteers after informed consent and split into matched 5 mL
samples. One sample of each matched pair was treated with 15 lg/mL docetaxel,
and the other sample was treated with vehicle control. Samples were placed in
BSA-blocked test tubes and placed on a rocker at 37 C for 24 h. Buffy coats were
isolated by Ficoll density centrifugation, washed, and suspended in calcium-
saturated PBS. Samples were processed and stained in an identical manner to that
used for CTC capture. For the determination of capture efﬁciency, 5 mL of whole
blood was drawn from four healthy volunteers and the buffy coats isolated. The buf-
fy coats were washed and suspended in calcium-saturated PBS. 1000 BT20 cells
were added to each sample and immediately processed through the CTC capture
device. Staining was carried out in an identical manner as that used for CTC capture,
described below.2.5. Spiking of cancer cell line cells into blood
Cancer cell line cells were spiked in blood, treated with chemotherapeutic
drugs, and then isolated. This process is depicted schematically in Fig. 1. Peripheral
blood was drawn from healthy volunteers after informed consent and transferred to
8 mL polystyrene round-bottomed tubes (BD Biosciences) in which the interior lu-
men had been blocked with 3% BSA for 1 h at room temperature. 50,000 breast can-
cer (BT20) or prostate cancer (PC3) cells were added to 5 mL of blood. The spiked
blood was then treated with vehicle control (dimethylsulfoxide, DMSO) or one of
three drug dosages based on published pharmacokinetic data (20% of peak plasma
concentration (PPC), 100% PPC, and 300% PPC). Breast cancer spiked blood was trea-
ted with docetaxel (1 lg/mL, 5 lg/mL, 15 lg/mL) or doxorubicin (0.2 lg/mL, 1 lg/
mL, 3 lg/mL); prostate cancer spiked blood was treated with docetaxel or mitoxan-
trone (0.1 lg/mL, 0.5 lg/mL, 1.5 lg/mL). Peak plasma concentrations are known
from previous pharmacokinetic studies [34–36]. Samples were incubated for 24 h
at 37 C on a BioRad UltraRocker rocking platform (Hercules, CA).2.6. Cell isolation and enumeration from spiked blood
Buffy coat was extracted from spiked blood using a Ficoll density centrifugation
as previously described [18]. Brieﬂy, buffy coat was washed in HBSS and any
remaining red blood cells were lysed with erythrocyte lysis buffer for 10 min at
room temperature (RT). Cells were washed with HBSS and resuspended in 2 mL
of ﬂow buffer. Flow buffer was prepared by saturating PBS containing Ca2+ and
Mg2+ with CaCO3, followed by sterile ﬁltration through a 0.2 lm PFTE syringe ﬁlter
(Millipore). Cells were perfused through the selectin-functionalized microtube de-
vice at a shear stress of 2 dyn/cm2. After ﬂow, the microtube devices were washed
with cell-free ﬂow buffer, and adherent cells were removed from the tube by intro-
ducing trypsin for 10 min at RT. The recovered cells were plated onto glass bottom
petri dishes (Grenier Bioone, Frickenhausen, Germany) and allowed to recover in
media supplemented with 30% FBS for 4 h.
Cells were ﬁxed in 4% paraformaldehyde for 45 min at RT. Plates were incubated
with anti-EpCAM antibody conjugated to FITC diluted 1:100 in PBS for 1 h at RT fol-
lowed by incubation with anti-CD45-APC antibody diluted 1:100 for 45 min at RT.
DAPI was added and the plates were imaged using an Olympus IX81 ﬂuorescence
microscope (Center Valley, PA) or Zeiss LSM710 confocal microscope (Oberkochen,
Germany) within the Life Science Core Facility at Cornell University. Cell counts
were based on EpCAM and CD45 expression, nucleus size and shape, and cell size
and morphology. A CTC was taken as any cell that met the following requirements:
greater than 8 um in size, nonsymmetrical nucleus, positive for EpCAM, negative for
CD45. Fluorescent micrographs were taken at 20 randomly selected locations with-
in each well, and total cell counts estimated based on the total well area [18].
Processed cells that were not captured in the tube were collected, washed with
PBS, and incubated with anti-EpCAM-FITC (clone 158206) for 1 h at RT. Stained cells
were subsequently washed and stained with annexin-V and propidium iodide
according to manufacturer instructions. Quantiﬁcation was carried out using a Mil-
lipore Guava Easycyte ﬂow cytometer.
2.7. Patient sample isolation
Two tubes of peripheral whole blood (7.5 mL per tube) were collected from
patients diagnosed with stage IV cancer by BioCytics Inc. at Carolina BioOncology
Institute, PLLC, after informed consent. Patients were enrolled on Western IRB-
approved Biocytics Protocol #0001 entitled ‘‘Pilot Study to Facilitate Development
of an Ex Vivo Device Kit for Circulating Tumor Cell Harvesting, Banking, and
Apoptosis-Viability Assay’’. See ClincalTrials.gov NCT# NCT00571389. Samples were
analyzed from 3 breast cancer patients (Br1 through Br3), 2 prostate cancer patients
(Pr1 and Pr2), one renal cancer patient (Re1), and one colon cancer patient (Co1).
Samples were shipped overnight to Cornell University where they were split into 3
2.5 mL samples and treated with vehicle control, subclinical (20% PPC), or clinical
dosages (100% PPC) of drug. Drugs were selected based on the cancer type. Prostate
sampleswere treatedwith docetaxel andmitoxantrone; breast, colon, and renal sam-
ples were treated with docetaxel and doxorubicin. Samples were processed and
enumerated in the precise manner as in cell spiking experiments as described above.2.8. EpCAM and sialyl Lewisx expression following drug treatment
In order to determinewhether the reduction in captured cellswas from cell death
or loss of adhesion ability, the expression of EpCAMand sialyl Lewisx, a selectin ligand
moiety, wasmeasured after drug treatment. BT20 cells were plated on 24well plates
in blood plasma isolated from healthy blood for 24h. Cells were then treated in
plasmawith the same dosages and drugs as in blood spiking experiments. The plates
were incubated for 4 h at 37 C. The cells were released from the plateswith enzyme-
free cell dissociation buffer (Life Technologies). Cells were stained with a 1:100
dilution of anti-EpCAM conjugatedwith FITC (clone HEA-125), or 10 lg/mL anti-sLex
for 30min on ice. Cells stainedwith anti-sLexwerewashed twice and counterstained
with anti-mouse IgG conjugated to Alexa 488 (Life Technologies) for 30 min on ice.
Cells were washed twice with buffer and analyzed using a ﬂow cytometer.
Fig. 1. Schematic of CTC analysis protocol.
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Fig. 2. Breast and prostate cancer cell lines are sensitive to docetaxel, doxorubicin, and mitoxantrone in vitro. Results are presented as the ratio of viable cells following 24 h
of drug administration to the number of viable cells in the control sample. (A) BT20 cells treated with docetaxel. (B) BT20 cells treated with doxorubicin. (C) PC3 cells treated
with docetaxel. (D) PC3 cells treated with mitoxantrone. Figures are representative of two independent experiments.
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Fig. 3. Breast and prostate cancer cell lines were spiked into 5 mL whole blood and treated with various doses of drugs. Following 24 h incubation, cancer cells were isolated
from the blood and enumerated. Results are presented with individual donor data represented by black lines and the mean capture by a red dotted line. (A) BT20 cells treated
with docetaxel. (B) BT20 cells treated with doxorubicin. (C) PC3 cells treated with docetaxel. (D) PC3 cells treated with mitoxantrone. (E) Representative micrographs of PC3
cells captured from blood samples treated with docetaxel. Cells were stained for EpCAM (green), CD45 (red), and nucleus (DAPI). Error bars represent standard error of the
mean. P < 0.05, P < 0.01, P < 0.001; scale bar = 50 lm.
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Cells were plated on 24 well plates and treated with drug at the same concen-
trations used in the isolation studies for 24 h at 37 C. Cells were released from the
plate with trypsin and washed with buffer. Cells were then diluted 1:10 in ViaCount
viability reagent and incubated for 10 min at RT, according to the manufacturer
instructions. The samples were then processed on a ﬂow cytometer using built-in
ViaCount software.
2.10. Statistics
Allgraphicalerrorbarsrepresentstandarderrorofthemean.Signiﬁcancewasdeter-
mined by performing an unpaired two-tailed t-test with a = 0.05 in GraphPad Prism.3. Results
3.1. BT20 and PC3 cells showed dose dependent susceptibility to
chemotherapeutic drugs in vitro
Chemotherapeutic drugs of interest (docetaxel, doxorubicin,
mitoxantrone) were tested for their efﬁcacy in vitro prior to testing
the drugs in situ in whole blood (Fig. 2). Data are expressed as the
number of viable cells relative to the untreated sample. BT20
showed dose-dependence, and this effect reached a plateau at
50% viability with docetaxel. A similar effect occurred with doce-
Table 1
Experimental data detailing the number of cells captured from cell spiking in whole blood. PPC = 5 lg/mL docetaxel (DT), 1 lg/mL doxorubicin (DOX), and 0.5 lg/mL
mitoxantrone (MTX).
Cell Line Treatment Donor Control 20% PPC 100% PPC 300% PPC
BT20 DT A 1522 ± 136 987 ± 81 487 ± 42 820 ± 114
BT20 DT B 2597 ± 186 2222 ± 289 1347 ± 97 1469 ± 173
BT20 DT C 1906 ± 139 1147 ± 82 914 ± 67 624 ± 45
BT20 DOX A 2276 ± 116 2717 ± 142 1857 ± 118 1883 ± 110
BT20 DOX B 2539 ± 121 2499 ± 103 1228 ± 100 837 ± 59
BT20 DOX C 1521 ± 72 514 ± 50 754 ± 51 632 ± 33
PC3 DT A 1251 ± 112 890 ± 105 500 ± 68 1043 ± 120
PC3 DT B 4260 ± 437 4095 ± 300 2006 ± 355 2006 ± 455
PC3 DT C 3992 ± 422 3662 ± 400 1512 ± 184 2020 ± 241
PC3 MTX A 6019 ± 572 4178 ± 494 2529 ± 332 2419 ± 332
PC3 MTX B 2419 ± 247 2721 ± 332 1759 ± 224 1127 ± 176
PC3 MTX C 7778 ± 1039 5937 ± 518 3848 ± 690 5964 ± 861
Fig. 4. EpCAM and sialyl Lewisx (sLe(x)) expression of BT20 cells did not change following treatment with docetaxel or doxorubicin, as evaluated by ﬂow cytometry. Data is
presented in histograms wherein the black shaded region represents isotype control, the blue line is the control untreated sample, the red line is the 20% PPC, the orange line
is 100% PPC, and the green line is 300% PPC. (A) EpCAM expression on cells treated with docetaxel (A) and doxorubicin (B) sLe(x) expression on cells treated with docetaxel (C)
and doxorubicin (D). Figures are representative of three independent experiments.
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cin and BT20 as well as with mitoxantrone and PC3, where viability
was reduced to 3% and 1.5%, respectively.
3.2. Spiked BT20 cells are captured at high efﬁciency and identiﬁed
with high speciﬁcity
1000 BT20 cells were spiked into buffy coat samples from four
healthy volunteers and the mean recovery determined to be
82.0 ± 9.4% (mean ± SEM, Supplemental Fig. 1). Buffy coat samples
were processed in an identical manner without spiked cells to
determine false positive rates. The mean number of positively
stained cells recovered from donor samples was 16.5 ± 9.4 cells
per donor with no drug treatment, and 0 cells following treatment
with 15 lg/mL docetaxel in matched samples.
3.3. BT20 and PC3 cells showed drug dependent susceptibility to
chemotherapeutic drugs in whole blood
50,000 BT20 or PC3 cells were spiked into whole blood, treated
with appropriate chemotherapeutic drug, and isolated as described
above. The clinical dosage of each drug was taken to be the maxi-
mum plasma concentration determined by previous pharmacoki-
netic studies [34–36]. BT20 cells were treated with docetaxel
(1 lg/mL, 5 lg/mL, 15 lg/mL) and doxorubicin (0.2 lg/mL, 1 lg/
mL, 3 lg/mL). Cell counts of BT20 treated with docetaxel were re-
duced to 70.2 ± 5.4% (mean ± SEM), 43.9 ± 2.7%, and 47.7 ± 4.1% of
the untreated sample. When treated with doxorubicin, cell counts
decreased to 83.9 ± 3.8%, 59.9 ± 3.0%, and 52.4 ± 2.5%, with respect
to the untreated control. PC3 cells were treated with docetaxel and
mitoxantrone (0.1 lg/mL, 0.5 lg/mL, 1.5 lg/mL). Docetaxel treat-
ment of PC3 cells reduced the cell count to 86.3 ± 7.1%,41.7 ± 4.4%, and 60.3 ± 6.2% of control, while mitoxantrone treat-
ment counts were 86.1 ± 8.0%, 54.7 ± 5.9%, and 54.5 ± 6.2% of the
untreated control (Fig. 3, Table 1).
To conﬁrm that the uncaptured cells were indeed rendered not
viable rather than just non-adhesive, the cells from the syringe that
did not stick to the tube were stained with annexin-V and propidi-
um iodide. No signiﬁcant number of viable EpCAM-positive cells
were observed in any of the samples studied (data not shown).
3.4. Chemotherapeutic drug treatment did not cause loss of EpCAM or
sialyl Lewisx expression
It was investigated whether the reduction of isolated cells as a
result of drug treatment was due to drug efﬁcacy or to simply loss
of adhesion markers. To address this, the surface expression of Ep-
CAM and sialyl Lewisx (sLe(x)) on BT20 cells was tested following
drug treatment by ﬂow cytometry (Fig. 4). No signiﬁcant change
in expression was seen post-treatment for any of the drug concen-
trations. This suggests that the reduced cell counts in drug treated
samples were due to reduction in the number of viable cells rather
than a loss of adhesion afﬁnity per se.
3.5. Primary cancer blood samples show heterogeneous susceptibility
to chemotherapeutic drugs
To investigate the relevance of this platform for clinical use, we
tested primary blood samples from 7 cancer patients (3 breast, 2
prostate, 1 colon, 1 renal). Subclinical and clinical dosages were
tested. Breast, colon, and renal blood samples were treated with
docetaxel and doxorubicin, while prostate cancer blood was trea-
ted with docetaxel and mitoxantrone (Fig 5; Table 2). Overall, drug
susceptibility for at least one of the drugs tested in 6 of 7 patients
Fig. 5. Patient samples were collected from three breast cancer patients (Br1, Br2, and Br3), two prostate cancer patients (Pr1 and Pr2), one renal and one colon cancer patient
(Re1 and Co1, respectively). Each tube of whole blood was split into three aliquots and treated with vehicle control, 20% PPC, or 100% PPC of the appropriate drug.
DT = docetaxel, DOX = doxorubicin, MTX = mitoxantrone. Error bars represent standard error of the mean. P < 0.05, P < 0.01, P < 0.001; scale bar = 50 um. Representative
micrographs of CTC capture from patient Pr2 and Re1 show the reduction in CTC count following drug treatment. Scale bars = 50 lm.
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of the drugs tested (Co1, Re1, Br3) while the CTC from another 3
patients were susceptible to both (Br1, Br2, Pr2). The remaining pa-
tient (Pr1) was not susceptible to either drug tested.
4. Discussion
In this paper a novel platform is presented for the prediction of
cancer drug efﬁcacy on a patient-to-patient basis, in a manner suit-able for pre-screening prior to systemic administration. This plat-
form was ﬁrst characterized by spiking breast and prostate
cancer cell lines at known quantities into healthy blood, creating
model samples of blood containing cancer cells with well-deﬁned
susceptibilities. Based on studies of drug efﬁcacy on these cell lines
in media (Fig. 2), we were able to recapitulate the therapeutic ef-
fect in whole blood (Fig. 3). It is interesting to note that the effect
of doxorubicin and mitoxantrone at their highest dosages was to
eliminate nearly all cancer cells in media, however in whole blood
Table 2
Experimental data the number of cells captured from cancer patient blood samples.
PPC = 5 lg/mL docetaxel (DT), 1 lg/mL doxorubicin (DOX), and 0.5 lg/mL mitoxan-
trone (MTX).
Donor Treatment Control 20% PPC 100% PPC
Br1 DT 7998 ± 905 2336 ± 255 1759 ± 423
Br1 DOX 4672 ± 609 – 715 ± 120
Br2 DT 4288 ± 423 3188 ± 365 1429 ± 241
Br2 DOX 3188 ± 318 3106 ± 563 989 ± 167
Br3 DT 9372 ± 550 5552 ± 550 7861 ± 879
Br3 DOX 8273 ± 533 4453 ± 449 3710 ± 473
Pr1 DT 7476 ± 524 9455 ± 1093 8768 ± 1070
Pr1 MTX 8300 ± 603 7146 ± 722 7531 ± 886
Pr2 DT 110765 ± 10,336 52,826 ± 5043 74,952 ± 4918
Pr2 MTX 156087 ± 10,276 87,622 ± 9860 52,606 ± 8115
Re1 DT 13,486 ± 576 11,076 ± 1011 12,423 ± 1345
Re1 DOX 11,269 ± 1034 6019 ± 486 5882 ± 843
Co1 DT 2749 ± 255 2529 ± 247 1072 ± 205
Co1 DOX 2446 ± 209 1292 ± 140 1677 ± 332
34 A.D. Hughes et al. / Cancer Letters 352 (2014) 28–35there was no signiﬁcant increase in cell elimination in response to
the clinical dosage. The observed limit of efﬁcacy to about 50% via-
bility is likely due to various factors present in the milieu of whole
blood. This underscores another advantage of our system, speciﬁ-
cally that drug efﬁcacy may be tested in the same environment
in which it is actually administered. The dose dependence of treat-
ment observed also demonstrates that it may be possible to iden-
tify patients that would respond to subclinical dosages at a level of
efﬁciency equal to the maximum dosage, ameliorating detrimental
side effects associated with chemotherapeutic toxicity.
A high degree of spiked cancer cell loss was observed following
incubation of blood samples for 24 h on a rocker. The observed cap-
ture efﬁciency of 82% (Supplemental Fig. 1) strongly suggests that
cell loss is due to cell death. Loss of cell viability is most likely due
in part to the fact that the test tubes were thoroughly blocked with
BSA and the motion of the blood from the rocker prohibited cell
adhesion, contributing to in cell death via anoikis [23,24]. Further
cell death is likely the result of inhospitable factors within the
whole blood collected from healthy volunteers, which would ex-
plain the relatively high degree of variability between donors (Ta-
ble 1). Nonetheless, we were able to detect a therapeutic reduction
in cell number, which is signiﬁcant due to the fact that all compar-
ative samples were matched. This is not expected to be the case for
clinical samples since the cancer cells are not foreign transplants
from a different donor but native to the patient, and, additionally,
primary cancer cells have been shown to avoid anoikis by various
mechanisms [24,25], and can escape immune activity [26–28].
Signiﬁcant quantities of CTC were detected in blood samples of
7 patients diagnosed with metastatic cancer (Fig. 5). Of these, 6
showed a marked reduction in CTC count following enumeration,
and of these 6 samples, three of them showed CTC reduction in re-
sponse to one of the two drugs tested. The fact that 3 out of 7 of the
samples responded differently to different drugs when treated in
an identical manner otherwise suggests that these results are in
fact due to sensitivities of the CTC. While all of the patient samples
analyzed showed distinctly high CTC counts, one patient had
exceptionally high counts: Pr2. It is interesting to note that Pr2,
which showed much higher CTC counts than Pr1, also had a much
higher PSA level of 2149 ng/mL compared to 643 ng/mL for Pr1. It
is important to note that this study was designed to assay drug
sensitivity. Reduction in CTC capture is a likely indication of drug
sensitivity in the patient, however negative results are not conclu-
sive of drug resistance in the patient. It remains to be seen if our
technique provides a true predictor of therapeutic response of pri-
mary tumor and metastatic lesions. Nevertheless, the assay is in-
tended to be carried out in a relevant biological environmentrather than an engineered environment, which may be a necessary
step to development of a successful predictive clinical tool.
Clinical trials have been performed and more are in progress
that monitor CTC count throughout the treatment of different co-
horts of patients. It has been shown that CTC count is a reliable pre-
dictor of response and relapse [29,30]. The combination of these
clinical trial ﬁndings with the suggestion that CTC may be the most
deadly subpopulation of cancer cells (in that they propagate
metastasis) makes CTC a particularly promising substrate for the
development of personalized medicine determination in the clinic
[31]. The assay developed here has the potential to be used in a
number of ways. Patient cohorts could be selected based on drug
sensitivity pre-screening. Alternatively, acquired resistance to che-
motherapeutics can be monitored throughout the progress of clin-
ical trials. Furthermore, as we have shown here for the
administration of docetaxel and doxorubicin to renal and colon
cancers, this platform allows for rapid screening of drugs approved
for some cancers but remaining to be evaluated for others. This is
particularly useful considering recent observations by the Cancer
Genome Atlas Research Network that cancers from different tis-
sues can have strikingly similar genetic signatures [32,33].
In conclusion, we have developed a novel platform for screening
drug efﬁcacies of chemotherapeutics using CTC enumeration as a
diagnostic output and a predictor for drug susceptibility in individ-
ual patients. BT20 and PC3 cells were spiked into whole blood and
treated with the purpose of validating this technique. The assay is
carried out in a rapid procedure that, in a clinical setting, could pre-
dict a patient’s sensitivity in a single day. Two doses of two thera-
peutic agents were assayed simultaneously in this study; scale up
to test more drugs is limited only by the quantity of blood that can
be drawn from a patient and the required sample volume per test.
Additionally, this technique is not limited to the isolation tech-
nique used in this paper; it can be adapted to any CTC detection
or isolation method.
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